NICE "inconsistent": Roche to appeal negative Tarceva guidance
10 March 2011
Francesca Bruce
Please Login to read the full article.
10 March 2011
Francesca Bruce
Please Login to read the full article.
RELATED CONTENT
NEWS
- NICE drug wars: Tarceva vs Iressa, Revlimid vs IFN alpha, Botox vs SoC, and others
- Roche convinces NICE to add 'incremental' Tarceva as NSCLC treatment option
- NICE no for Tyverb and Herceptin in breast cancer, Roche considers appeal
- NICE still down on overall survival benefit of Roche's Herceptin and GSK's Tyverb following appeal
ANALYSIS
Other Informa Analysis
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
